MedTrace Logo

Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN)

NCT06122922 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-01-23

No results posted yet for this study

Summary

The objective of this project is to determine how pulmonary vascular remodeling in Pulmonary Arterial Hypertension (PAH) at cellular and pathological level is associated with gas exchange physiology changes and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.

Conditions

  • Pulmonary Artery Hypertension

Interventions

DRUG

Hyperpolarized Xe129

Hyperpolarized Xenon Gas

Sponsors & Collaborators

Principal Investigators

  • Sudarshan Rajagopal, MD · Duke University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06122922 on ClinicalTrials.gov